Phase 3 N=296 Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
Neoplasms, Breast
Primary: Progression-Free Survival (PFS) — 12.0; 8.1 weeks — p=0.008
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=859 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge Up to Day 6 — 51.8; 41.3 Percentage of Patients
Phase 3 N=231 Trial Comparing Effects of Xyrem Taken Orally and Modafinil With Placebo in Treating Daytime Sleepiness in Narcolepsy
Narcolepsy
Primary: Daytime Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — -2.72; 0.58; -0.53; 2.68 Minutes — p=<0.001
Phase 3 N=548 A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia
Fibromyalgia
Primary: Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF). — 27.3; 46.2; 39.3; 72.7…
Phase 3 N=578 A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis
Bacterial Conjunctivitis
Primary: Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6 — 74.9; 65.2 Percentage of Patients
Phase 3 N=422 Comparison of Liraglutide Versus Placebo in Weight Loss Maintenance in Obese Subjects: SCALE - Maintenance
Metabolism and Nutrition Disorder · Obesity
Primary: Mean Percentage Change in Fasting Body Weight From Baseline — -6.11; -0.05 percentage — p=<0.0001
Phase 3 N=583 Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Parkinson's Disease Dementia
Primary: Percentage of Participants With Adverse Events (AEs) Due, or Potentially Due, to Worsening of Parkinson Disease (PD) Motor Symptoms (Tremor, Muscle Rigidity…
Phase 3 N=65 Portion Control Treatment for Obesity
Obesity
Primary: Weight Change at 6 Months — -1.2; -0.4 percentage — p=0.31
Phase 3 N=57 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Immune Thrombocytopenic Purpura
Primary: Platelet Response — 80.7 Percent of participants
Phase 3 N=2,204 Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Essential Hypertension
Primary: Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg — -6.1; -7.1; -8.9 mm Hg — p=0.1187
Phase 3 N=1,002 A Multinational Phase III Study of CS-8958 (MARVEL)
Influenza, Human
Primary: Time to Alleviation of Influenza Illness — 73.0; 85.8; 73.6 hours — p=0.748
Phase 3 N=230 Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Acute Gout
Primary: Time to First New Flare — NA; NA Days
Phase 3 N=120 Immunogenicity & Safety Study of Fluviral® (2010 - 2011 Season) in Adults Aged 18 to 60 Years and Over 60 Years
Influenza
Primary: Geometric Mean Titers (GMTs) of Haemagglutination Inhibition (HI) Antibodies Against Fluviral Vaccine Strains. — 39.2; 15.2; 14.1; 13.0 Titer
Phase 3 N=675 A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Malignant Melanoma
Primary: Overall Survival — 43; 75; 293; 261 participants — p=<0.0001
Phase 3 N=81 Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
Osteoporosis · Postmenopausal
Primary: Change in Bone Mineral Density (BMD) From Baseline to Month 36 — -0.11; 0.03 Percent